Idiopathic Pulmonary Fibrosis (IPF)
Conditions
Interventions
Non-IPF and non-lung deficiency and collateral stasis syndrome (COPD with phlegm-heat obstructing lung syndrome) group:none
IPF with lung deficiency and collateral stasis syndrome group:none
Sponsors
The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine Shenyang Liaoning
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) Aged 40 to 85 years regardless of gender; 2) Meeting the diagnostic criteria for idiopathic pulmonary fibrosis (IPF) with lung deficiency and collateral stasis syndrome or chronic obstructive pulmonary disease (COPD) with phlegm-heat obstructing lung syndrome; 3) Healthy subjects meeting physical examination standards; 4) Not having participated in any other interventional trials within 1 month prior to enrollment; 5) Providing signed informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with idiopathic pulmonary fibrosis (IPF) who have evidence of significant obstructive pulmonary disease: Forced Expiratory Volume in 1 Second (FEV1)/Forced Vital Capacity (FVC) < 0.70, or computed tomography (CT) showing that the degree of emphysema is greater than that of fibrosis; 2) Patients who had a lower respiratory tract infection within 4 weeks before the baseline period and/or during the screening period, requiring treatment with antibiotics or inhaled corticosteroids; or patients receiving treatment with pirfenidone or nintedanib; 3) Patients with current diagnosis of any malignant tumor, or a history of any malignant tumor that may be life-threatening or require major medical or surgical intervention within the next year; 4) Patients with acute exacerbation of IPF or in the advanced/critical stage of IPF; 5) Patients concomitant with other primary lung diseases (e.g., bronchial asthma, lung cancer); 6) Patients concomitant with severe primary diseases of the cardiovascular system, kidneys, liver, or other organs; 7) Patients concomitant with acute conditions such as bleeding or fever; 8) Pregnant or lactating women, or patients with plans for pregnancy in the near future; 9) Patients deemed unsuitable for inclusion by the investigator (e.g., patients with mental illness);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolomic analysis of plasma;Proteomic analysis of plasma;Metabolomic analysis of bronchoalveolar lavage fluid;Proteomic analysis of bronchoalveolar lavage fluid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical data (general information symptoms signs tongue and pulse diagnostic information); | — |
Countries
China
Contacts
Public ContactLYU Xiaodong
Liaoning University of Traditional Chinese Medicine
Outcome results
None listed